All Posts Tagged With: "SGP"
(RX) Big Pharma and Biotech – Industry Outlook
The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between...
9Nov2009 | Shawn | 0 comments | Continued(MRK) Merck and Schering-Plough Earn Merger Approval
Recently, Merck (MRK) and Schering-Plough (SGP) received approval from the US Federal Trade Commission [FTC], the Swiss Competition Commission and the Canadian Competition Bureau for their proposed merger. However, the transaction has yet to receive approval from other regulators...
1Nov2009 | vitalstocks | 0 comments | Continued(VRTX) Vertex Pharmaceuticals Posts Wider Loss
Vertex Pharmaceuticals (VRTX) posted a loss of 83 cents per share in the third quarter, 3 cents wider than the Zacks Consensus Estimate of a loss of 80 cents. The company posted a loss of 92 cents per share in the year ago period. The wider than expected loss was mainly due...
27Oct2009 | vitalstocks | 0 comments | Continued(SGP) Schering-Plough Reports In-line Earnings
Schering-Plough Corp. (SGP) reported third-quarter earnings of 40 cents per share, which was in-line with the Zacks Consensus Estimate. Although earnings came in a cent above the year-ago level, revenues declined 2% to $4.5 billion mainly due to an unfavorable foreign exchange...
22Oct2009 | vitalstocks | 0 comments | Continued($MRK) Merck Extends Galapagos Alliance
The existing alliance between Merck (MRK) and Belgian biotech company Galapagos over metabolic diseases was recently expanded to develop new therapies for atherosclerosis, or hardening of arteries due to cholesterol build-up. Following the deal, Galapagos will be eligible to...
16Oct2009 | vitalstocks | 0 comments | Continued(SGP) Schering-Plough Corporation Inks Deal With Opko Health
Recently, Schering-Plough Corporation (SGP) and Opko Health Inc. (OPK) entered into a deal which would enable Opko to acquire the assets of Schering’s neurokinin-1 (NK-1) receptor antagonist program. The companies did not disclose the terms of the agreement. NK-1 receptors...
15Oct2009 | vitalstocks | 0 comments | Continued(SEPR) Dainippon-Sepracor Deal Emerges
Today, Dainippon Sumitomo and Sepracor (SEPR) have announced the successful completion of the initial share offering period, where almost 78.2% of Sepracor’s shares were tendered. The offer period has been extended to Oct 19, 2009, to enable other shareholders to tender their...
15Oct2009 | vitalstocks | 0 comments | Continued(SNTS) Santarus Signs Deal with Norgine
This morning, Santarus, Inc. (SNTS) entered into a licensing agreement with Norgine B.V., a European specialty pharmaceutical company. Under the licensing agreement, Norgine has been granted exclusive rights for the development, manufacture and commercialization of prescription...
13Oct2009 | vitalstocks | 0 comments | Continued(ENZN) Enzon Pharma Announces European Approval for Cimzia
Yesterday, Enzon Pharma (ENZN) announced the European Commission approval of UCB’s Cimzia (certolizumab pegol) for the treatment of adult patients with moderate-to-severe active rheumatoid arthritis (RA). Cimzia utilizes Enzon’s PEGylation technology. Earlier in May 2009,...
8Oct2009 | vitalstocks | 0 comments | Continued(SGP) Schering-Plough and Johnson & Johnson Score European Union Drug Approval
Yesterday, Schering-Plough Corp. (SGP) and Johnson & Johnson (JNJ) announced the approval of their drug Simponi (golimumab) in the European Union for the treatment of rheumatoid arthritis and other immune system disorders. The drug was approved by the U.S. Food and Drug Administration...
7Oct2009 | vitalstocks | 0 comments | Continued(MRK) Merck Seeks European Union Approval of its Schering-Plough Purchase
Yesterday, Merck & Co. (MRK) announced that it is seeking approval from the European Union (EU) for its $41.1 billion acquisition of Schering-Plough Corp. (SGP). The regulatory authorities in the EU are expected to pass a verdict on the matter by Oct. 23. Merck filed for...
23Sep2009 | vitalstocks | 0 comments | Continued(ANDS) Anadys Begins Mid-Stage Trial
Yesterday, Anadys Pharmaceuticals Inc. (ANDS) started a 12-week phase II trial of its ANA598 for hepatitis C patients. ANA 598 will be evaluated in combination with interferon-alpha and ribavirin (current standard of care) in the mid-stage study. Data from the trial is expected...
11Sep2009 | vitalstocks | 0 comments | Continued(SEPR) Dainippon Sumitomo Pharma Acquires Sepracor
Today morning, Japanese pharmaceutical company Dainippon Sumitomo Pharma Co., Ltd. confirmed that it signed a definitive agreement to buy U.S. pharmaceutical company Sepracor Inc. (SEPR). The deal has been valued at $23 per share or $2.6 billion. The market was abuzz with rumors...
3Sep2009 | vitalstocks | 0 comments | Continued(MRK) Merck Announces New Management Structure for Schering-Plough Merger
With the merger of Merck (MRK) and Schering-Plough (SGP) scheduled to be completed by the fourth quarter this year, Merck is busy with the necessary groundwork. Yesterday, the company announced the new management structure post merger. The current chairman, president and CEO...
1Sep2009 | vitalstocks | 0 comments | Continued(SGP) Euro Review for Schering Drugs
Yesterday, Schering-Plough Corp. (SGP) revealed that the European Medicines Agency (EMA) will review its candidate for maintenance treatment of asthma in patients 12 years and above and an oral contraceptive for marketing in Europe. While the fixed-dose combination of mometasone...
27Aug2009 | vitalstocks | 0 comments | Continued(LGND) Ligand Pharmaceuticals to Buy Neurogen
Yesterday, Ligand Pharmaceuticals Inc. (LGND) announced it has agreed to purchase Neurogen (NRGN) for $11 million in stock as well as certain future cash payments based on licensing deals, real estate sales and other milestones. The deal, which is expected to close by the fourth...
25Aug2009 | vitalstocks | 0 comments | Continued(SGP) Schering-Plough Settles Lawsuits – Analyst Blog
Yesterday, Schering-Plough Corp. (SGP) said it has signed an agreement with Orchid Chemicals & Pharmaceuticals Ltd. and Orgenus Pharma Inc., which sought to make generic versions of its allergy drug Clarinex. This signals the end of all pending litigations that Schering filed...
12Aug2009 | vitalstocks | 0 comments | Continued(PFE) Pharmaceuticals & Biotech – Zacks Analyst Interviews
The pharmaceutical industry is entering a period of substantial change in 2009. Most of the names in the industry are facing significant patent challenges in the years to come. U.S.-based firms are facing foreign exchange headwinds, as well. Revenue growth is non-existent, and...
9Jun2009 | vitalstocks | 0 comments | Continued(PFE) Pharmaceuticals & Biotech – Industry Outlook
The pharmaceutical industry is entering a period of substantial change in 2009. Most of the names in the industry are facing significant patent challenges in the years to come. U.S.-based firms are facing foreign exchange headwinds, as well. Revenue growth is non-existent, and...
8Jun2009 | vitalstocks | 0 comments | Continued(MRK) Drug Companies: A Powerhouse of Profits
by The Investment U Research Team A couple of interesting news items came out in the past few days. One, a research report showing how expensive treatment is for childhood mental issues. It also showed that in 2006 over 13 million children were treated for asthma at a cost...
9May2009 | InvestmentU | 0 comments | Continued(WYE) Biotech Industry – Industry Outlook
OVERVIEW The financial market and the economic landscape in the U.S. have not changed much since the beginning of the year. And we believe the status quo will last for a while at least in 2009. Large biotech companies are doing OK since they have strong balance sheets to weather...
13Mar2009 | vitalstocks | 0 comments | Continued